Universe Competitors
| UPC Stock | USD 3.98 0.41 9.34% |
Universe Pharmaceuticals vs NewcelX Correlation
Good diversification
The correlation between Universe Pharmaceuticals and NCEL is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Universe Pharmaceuticals and NCEL in the same portfolio, assuming nothing else is changed.
Moving against Universe Stock
| 0.48 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.47 | ABP | Abpro Holdings | PairCorr |
| 0.34 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.34 | KURA | Kura Oncology | PairCorr |
Universe Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Universe Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Universe and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Universe Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Universe Stock performing well and Universe Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Universe Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PRFX | 13.91 | 3.39 | 0.27 | 0.25 | 12.24 | 10.11 | 393.11 | |||
| NKGN | 4.98 | 2.05 | 0.00 | 5.97 | 0.00 | 20.00 | 68.90 | |||
| ELAB | 5.70 | (3.69) | 0.00 | (1.18) | 0.00 | 5.71 | 53.38 | |||
| BJDX | 3.99 | (1.37) | 0.00 | (0.82) | 0.00 | 8.08 | 31.63 | |||
| TIVC | 5.21 | (1.48) | 0.00 | (0.60) | 0.00 | 10.43 | 46.76 | |||
| WINT | 7.26 | (2.90) | 0.00 | (1.45) | 0.00 | 16.67 | 75.00 | |||
| MLEC | 9.26 | 0.37 | 0.04 | 0.17 | 11.03 | 15.63 | 152.55 | |||
| BCTXZ | 8.84 | (0.54) | 0.00 | 0.31 | 0.00 | 18.52 | 69.68 | |||
| SHPH | 7.05 | (0.46) | 0.00 | 0.25 | 0.00 | 15.69 | 44.53 | |||
| NCEL | 5.73 | (1.21) | 0.00 | (1.54) | 0.00 | 10.12 | 39.40 |
Cross Equities Net Income Analysis
Compare Universe Pharmaceuticals and related stocks such as Painreform, NKGen Biotech Common, and Elevai Labs Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRFX | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (828 K) | (1.8 M) | (4.1 M) | (7.2 M) | (8.8 M) | (9.3 M) | (14.6 M) | (13.1 M) | (12.5 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| BJDX | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (1.1 M) | (3.7 M) | (9.3 M) | (10 M) | (7.7 M) | (6.9 M) | (7.3 M) |
| TIVC | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (3.6 M) | (8.5 M) | (10.1 M) | (8.2 M) | (5.7 M) | (5.1 M) | (5.3 M) |
| WINT | (2.8 M) | (21 M) | (37.3 M) | (45.2 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (30.3 M) | (67.6 M) | (39.2 M) | (20.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| MLEC | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (4.5 M) | (51.8 M) | (7.3 M) | (111.5 M) | (100.3 M) | (95.3 M) |
| BCTXZ | (8.6 K) | (995.7 K) | (368.7 K) | (8.9 M) | (2.7 M) | (1.7 M) | (2.6 M) | (5.4 K) | (6.2 K) | 1.4 M | (2.9 M) | (11.6 M) | (20.3 M) | (6.6 K) | (36.5 M) | (32.8 M) | (31.2 M) |
| SHPH | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (626.1 K) | (805.7 K) | (805.7 K) | (1.2 M) | (5 M) | (6.6 M) | (9.1 M) | (8.2 M) | (7.8 M) |
| NCEL | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (5.1 K) | (5.4 M) | (2.9 M) | (11.9 M) | (16.5 M) | (12.2 M) | (2 M) | (1.8 M) | (1.9 M) |
Universe Pharmaceuticals and related stocks such as Painreform, NKGen Biotech Common, and Elevai Labs Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Universe Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Universe Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Universe Pharmaceuticals Competitive Analysis
The better you understand Universe Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Universe Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Universe Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Universe Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Universe Pharmaceuticals Competition
Universe Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Universe Pharmaceuticals in relation to its competition. Universe Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Universe Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Universe Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Universe Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Universe Pharmaceuticals position
In addition to having Universe Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Universe Pharmaceuticals Correlation with its peers. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Universe diversify its offerings? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Universe Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.82) | Earnings Share (7.83) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Universe Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.